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ABSTRACT 
 
 Abbott Bioresearch Center strives to characterize specific kinases in order to 
better understand the processes that take place in cells of the human body. The goal is to 
develop an inhibiting drug for a kinase pathway associated with a particular target 
disease. The main focus at Abbott is autoimmune diseases, including rheumatoid arthritis 
and pro-inflammatory diseases. This MQP details the initial process that each kinase goes 
through in order to understand compound inhibition under conditions that take into 
consideration the effects of a physiological environment, and shows the application to 
one specific kinase, COT. An inhibitor of the kinase was identified that acts in an ATP-
competitive manner. These processes allow for screening of thousands of compounds 
against any kinase that can be isolated and characterized. 
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BACKGROUND 
 
Introduction 
 Drug discovery makes advances in very different ways than do other consumer-
driven markets. With failure rates totaling in excess of 96%, the amount of resources and 
time that eventually produces one successful drug to market can span over a decade 
(Clark, 2003). While negative regulation of pathways may seem far easier than 
activation, most novel drugs are responsible for the inhibition of an over stimulated 
pathway. Abbott Bioresearch Center focuses on kinase pathways and inhibition at key 
points that will reduce or eliminate certain autoimmune and inflammatory responses. 
With large scale operations at major pharmaceutical companies like Abbott Laboratories, 
high throughput in vitro assays under physiological conditions are necessary to 
accommodate needs. 
 
The MAP Kinases and COT 
It is well known that the majority of autoimmune, inflammatory, and cancerous 
diseases result from abnormal regulation of mitogen activated protein kinase (MAPK) 
pathways (Karin, 2004). Since such a large number of diseases correlate to activation and 
inactivation of these complex pathways, pharmaceutical companies are spending time 
and money to decipher the relationships between individual kinases and entire signaling 
events involving tiered structures. Figure 1 is an edited image from the EMD Biosciences 
website highlighting the complexity of only a few of the MAPK pathways. Cancer Osaka 
thyroid (COT), referred to in the figure as Tpl-2 (analog), is a MAP3K residing at the top 
of the tiered structure. All  
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Figure 1: A portion of the kinase signaling pathway; red indicates MAP3Ks, green indicates MAP2Ks, and 
blue indicates MAPKs (EMD Biosciences website). 
 
MAP3Ks phosphorylate the MAP2Ks on the tier below them at a point in the amino acid 
sequence near both ATP and substrate binding sites (Clark, 2003). This map makes it 
clear that cellular signaling pathways are both complicated and finely tuned. Over or 
under expression at one point can have more than a single resulting effect. The negative 
regulation of COT is provided through the binding of inhibitor p105. p105, a direct 
transcription of the gene product from nfκb1 of the NF-κB family, produces a COT/p105 
complex that is inactive and stable within the cell (Waterfield et al, 2003). Activation of 
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COT requires the dissociation of p105, and consequential degradation; this ensures that 
the pathway will not remain active indefinitely (Beinke et al, 2003). 
 COT is itself a MAP3K, showing activity in the COT-MEK-Erk2 cascade (see 
MAPK tier in Figure 1) (Jia et al, 2005). The knockout model in mice, COT-/-, shows 
blocking of the MEK/Erk pathway, an indication of COT playing a vital role in both 
MEK (MAP2K) and Erk (MAPK) signaling (Jia et al, 2005). The phenotype of the COT-
/- knockout mouse is normal, except for the down regulation of pro-inflammatory 
cytokine production (Jia et al, 2005). For this reason, COT is currently a target for 
autoimmune disease research. 
 
Fluorescence Resonance Energy Transfer (FRET) 
 FRET technology provides an accurate interpretation of the signal generated by 
what are termed the donor and acceptor molecules (Figure 2). The simplest design is that 
of a donor (shown as red) being excited at a specific wavelength that results in an energy 
transfer to an acceptor (shown as blue).  
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Figure 2: The basic involvement of two molecules in the FRET absorption and emission; since both 
molecules emit over different wavelength ranges, the interference of Europium cryptate autofluorescence is 
kept at a minimum (Cisbio, 2002).  
 
FRET will only occur if the donor and acceptor are within a specific proximity, most 
commonly near 1-7 nm, the range at which energy transfer is 50% efficient (Cisbio, 
2002). Figure 2 illustrates how the process corrects for multiple fluorescing molecules. 
The Europium cryptate fluoresces at wavelengths (550nm – 630nm and 680nm – 
710nm), while the XL665 will fluoresce almost exclusively in the range from 640nm – 
680nm (Cisbio, 2002). By emitting over a different range of wavelengths, interference is 
brought down to a minimum. FRET being the theory of the energy absorption, transfer, 
and emission, there are many variations that explore various donor-acceptor pairs. The 
most applicable design for COT involves labeling an antibody donor with Europium 
cryptate and an acceptor, XL665 (Jia et al, 2005). This optimization of the FRET process 
was developed and patented by Cisbio International. Termed homogeneous time resolved 
fluorescence (HTRF), it abolishes some of the major drawbacks of basic FRET (Figure 
3). Similar to the need to distinguish between emission from the Europium cryptate and 
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XL665, HTRF emissions readings eliminate short-lived signals from both the media of 
the experiment and the unbound XL665. This time response property enables a clear 
isolation and detection of the FRET signal by delaying the reading of emissions, avoiding 
interference from the solution and individual components of the system (Figure 3) 
(Cisbio, 2002). To account for overall variance in experiments from one to another and 
day to day, the measurement of 665 nm / 620 nm is used. 
 
 
 
Figure 3: The basics of HTRF. The
media and the unbound XL665 both
emit short-lived signals that are
removed (yellow and blue,
respectively). The unbound Europium
cryptate emits a long-lived signal that
is accounted for in the signal ratio
(red). The complexed Europium
cryptate and XL665 emit a long-lived,
extremely strong signal (Cisbio,
2002). 
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Homogeneous Time Resolved Fluorescence (HTRF) for COT 
 As already mentioned, HTRF is an optimization of FRET technology for the COT 
assay, using Europium cryptate and XL665 labeling. The Europium cryptate labeled 
antibody (i.e. Eu-Anti-phospho-‘substrate’) is excited by a laser at 337 nm, producing an 
emission at 620 nm that is absorbed by the XL665 molecule (Clark, 2003). 
Figure 4: HTRF visualization indicating the Europium cryptate labeled antibody (1) and its affinity for the 
phosphorylated site (2) of the substrate (3). This brings it into close proximity with XL665 (6) through the 
interaction of the biotin (4) labeled end of the substrate and the streptavidin (5) labeled XL665. 
 
Before introduction to the reaction, the substrate is biotinylated while the XL665 is bound 
to streptavidin (SA) (Clark, 2003). Figure 4 illustrates how all of these individual parts 
come together, and how the release of an emission occurs. The substrate is 
phosphorylated at a specific site (2), enabling the attachment of the Europium cryptate 
labeled antibody (1). By labeling the XL665 with streptavidin, and the substrate molecule 
with biotin, the XL665 is essentially bound to the substrate itself (Figure 4). This ideal 
donor-acceptor pair leads to an efficiency of 50 – 95% for distances of 5 – 10 nm 
(compared with standard FRET efficiencies of near 50% and distances of 1 – 7 nm) 
(Cisbio, 2002). 
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 Enzyme Kinetics (Michaelis-Menton Kinetics) 
 The pioneers of steady state enzyme kinetics were Leonor Michaelis and Maud 
Menten; the kinetic constant KM is named after them, with the subscript 'm' representing 
their surnames. The most common illustration used for the mechanism of steady state 
kinetics is that of: 
(Equation 1) 
Where E is enzyme, S is substrate, ES is enzyme/substrate complex, and P is the product. 
k1 and k-1 are the rate constants for formation and degradation of the ES complex. k2 is 
the rate constant for the formation of the product P. The rate limiting step in the overall 
reaction is from ES ? E + P, or k2; this takes into consideration the second assumption: 
that the substrate concentration, [S], is in excess of the enzyme concentration [E], 
[S]>>[E] (Willmott, 2005). Thus, the velocity (or rate) of the reaction can be written as v 
= k2[ES]. Up to this point, it is important to remember that these equations are based 
upon the assumption that the substrate is in excess and that the system is in steady state. 
This means that the ES complex is being formed and broken down at the same rate. The 
mathematical visualization of this is k1[E][S] = (k-1 + k2)[ES]; this leads to: 
(Equation 2) 
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At this point, Michaelis and Menten combined all of the constants present in the equation 
into their own constant:  
(Equation 3) 
When the substitution is completed, the use of the inverse of the KM allows for a 
simplified view of Equation 2: 
(Equation 4) 
 In other words, the enzyme concentration multiplied by the substrate concentration, and 
then divided by the KM is equal to the concentration of the enzyme-substrate complex. 
 Next, it is important to mathematically determine the rate at which all enzyme has 
substrate bound. This is termed Vmax, or the point at which the velocity is at its 
maximum. Assuming that the total amount of available enzyme is [ET] and is equal to the 
amount of unbound enzyme [E] in addition to bound enzyme [ES], [E] + [ES] = [ET]. 
Rearrangement and substitution into the equation, and the insertion of v = k2[ES] results 
in Equation 5: 
(Equation 5) 
Considering the earlier statement that the substrate concentration is in excess of the 
enzyme concentration, it is valid to propose that Vmax can be substituted for v, and that 
[ET] can be substituted for [ES]; the resulting form of the original velocity equation now 
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becomes Vmax = k2[ET] (Willmott, 2005). Substituting this into the more complicated 
velocity equation derived earlier in this paragraph results in what is formally known as 
the Michaelis-Menten equation: 
(Equation 6) 
 The significance of this equation becomes clear through a visualization of the 
conditions when the rate of reaction (v) is half of the maximum rate of reaction (Vmax) 
(Willmott, 2005).  
Figure 4: Velocity versus substrate concentration curve showing that the KM is equal to the substrate 
concentration at which one half of the Vmax is reached. 
 
 
In this case, using v = Vmax/2 as a substitution into the Michaelis-Menten equation, 
simplifying produces the realization that under these conditions, the KM of a specific 
enzyme is the substrate concentration, [S], at half of the maximum rate. Steady state 
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kinetics requires an equilibrium during which substrate turnover is constant. This 
catalytic efficiency, referred to as kcat, is equal to Vmax/[E].  
  
Inhibitor Characterization 
 For each specific kinase target identified as a key point in a pathway of interest it 
is important to develop an assay that can be used to verify inhibitor potency/activity. 
There is a series of experiments that enable the development of an assay for 
characterization of compounds that may become future drug candidates. With many years 
of assay development and study, physiologically relevant conditions have been developed 
and can be applied to the majority of assay development protocols. 
 When a kinase is first acquired in a useable amount and concentration, it must be 
tested for activity. From one batch to the next, a kinase may experience drastic variability 
in robustness. A kinase titration is most often done by testing a series of serial dilutions 
of the kinase over a set amount of time. If the chosen concentrations extend high enough 
to reach complete saturation, it is then possible to identify the linear range for a chosen 
kinase. It is also important to have a signal to background ratio (referred to as the kinetic 
window) that is 5 to 10 fold (Clark, 2003). 
 To further understand the kinetics of the target kinase, and to make sure that 
linearity is available from 0 to 60 minutes at a specific enzyme concentration, a 
timecourse is needed. In cases where the chosen enzyme concentration is too high, the 
reaction will run to completion quickly and will not provide an adequate kinetic window. 
This period of linearity that is desired is referred to as steady state kinetics, and will be 
discussed in greater detail in the results section. 
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 After an enzyme concentration has been found that adequately supports steady 
state kinetics, the ATP KM must be determined in order to assist compound mechanistic 
studies. The decided upon conditions are used from the previous experiments, with the 
variable being the ATP concentration. A timecourse is run for a very wide range of ATP 
concentrations, and the slope calculated from each resulting concentrations becomes a 
single point on a graph. If done correctly, the graph will proceed to appear similar to 
Figure 4, and the ATP KM can be mathematically determined. Since the ATP KM value is 
a value directly related to the affinity of the target enzyme for ATP, it helps to further 
design experimental conditions for compound inhibition testing (IC50). 
 The IC50 of a specific compound is identified as the concentration of that 
compound producing 50% inhibition of the target enzyme. Referring back to the 
reasoning behind the ATP KM determination, it can be seen that the inhibition level of the 
compounds is relative to the experimental conditions used. If a step in the development 
process, from enzyme to ATP to substrate concentrations is not done correctly, it is likely 
that the results of the IC50 will be invalid. The most common indicator of such an event is 
inconsistent readings and ratios from experiments, as well as IC50 values that are not 
reliable from experiment to experiment. Based on steady state kinetic equations, it is 
possible to predict outcomes for most experiments, leading to early notification of 
incorrectly performed assays. 
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PURPOSE 
 With the recent identification of COT as a new target kinase, it is important to 
develop a useable high throughput assay to produce consistent IC50 data. For this reason, 
a series of experiments was developed to characterize this target kinase, including an 
understanding of its kinetic parameters. Once it has been isolated and purified, and these 
kinetic parameters calculated, compound inhibition can be done. 
 The purpose here is to describe the process used to develop an assay using HTRF 
technology. This series of experiments is applicable to nearly all kinases, and is used with 
the hopes of identifying an inhibitor that can become a drug candidate. The entire process 
is done with the assistance of medium and high throughput technology. Without such 
advancements as HTRF technology and 96- and 384-well plates, rapid advancement 
would not be possible. 
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METHODS 
 
Introduction 
 All reactions were adapted to a total reaction volume of 40 µL; this reaction 
volume was quenched with 10 µL of 0.5 M ethylenediaminetetraacetic acid (EDTA), a 
metal chelator that prevents further reaction. Developing solutions brought the total 
volume to 125 µL. Each point was performed in duplicate, and all experiments were done 
using Costar 96 half-well plates at room temperature. Dimethyl sulfoxide (DMSO) is an 
agent that is able to associate with most proteins, nucleic acids, ionic substances, and 
even water. For this reason it is commonly used as a stable storing medium for 
concentrated compounds. 10 µL of each reagent at 4x was used to produce 1x 
concentration under reaction conditions. For example: 10 µL of 4 mM ATP is added to a 
total volume of 40 µL, producing a reaction condition of 1 mM ATP. 
 
Enzyme Titration 
 DMSO was used in the reaction at a volume of 10 µL and a final concentration of 
5%. 10 µL of ATP was added, as well as 10 µL of chosen substrate. The enzyme was 
titrated in 1x RB by performing a serial 1:2 dilution of 10 steps, producing a large range 
of concentrations. The reaction was started by adding 10 µL of each enzyme to its 
respective well. After 60 minutes at room temperature, the reaction was stopped by 
adding 10 µL of 0.5 M EDTA to each well. Development of completed reaction involves 
addition of 75 µL of Revelation Buffer, consisting of the following components: 2 mM 
KF, 0.1% BSA, 0.01% Tween-20, SA-XL665, and Europium cryptate labeled antibody. 
Overnight development was allowed at 4°C. The plate was read using BMG 
Laboratories’ RUBYstar the following morning. Data analysis was done using Excel by 
Microsoft. 
 
Timecourse 
 Each well contained 10 µL of DMSO at a final concentration of 5%, 10 µL of 
ATP, and 10 µL of substrate. 10 µL of 0.5 M EDTA was added to the first well, creating 
a 0 time point. 10 µL of enzyme at was added to each well, starting the reaction. In order 
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to cover a wide range, several identical timecourses were run on the same plate with 
different enzyme concentrations. At time points between 0 and 80 minutes, at room 
temperature, 10 µL of 0.5 M EDTA was added to the corresponding wells. Development 
of completed reaction for HTRF reader involves addition of 75 µL of Revelation Buffer 
consisting of the following components: 2 mM KF, 0.1% BSA, 0.01% Tween-20, SA-
XL665, and Europium cryptate labeled antibody. Overnight development was allowed at 
4°C. The plate was read using BMG Laboratories’ RUBYstar the following morning. 
Data analysis was done using Excel by Microsoft. 
 
ATP KM Determination 
 Prepared 1x RB was used to perform a serial 1:2 dilution of ATP, providing an 
adequate range of final concentrations. 10 µL of corresponding ATP dilution was added 
to each well. 10 µL 5% final concentration DMSO was added to each well, as was 10 µL 
of substrate. 10 µL of enzyme was added to begin reaction. After 60 minutes of reaction 
time, at room temperature, the process was quenched by addition of 10 µL 0.5 M EDTA. 
Development of completed reaction involves addition of 75 µL of Revelation Buffer 
consisting of the following components: 2 mM KF, 0.1% BSA, 0.01% Tween-20, SA-
XL665, and Europium cryptate labeled antibody. Overnight development was allowed at 
4°C. The plate was read using BMG Laboratories’ RUBYstar the following morning. 
Data analysis was done using Excel by Microsoft. 
 
IC50 Determination 
 Stock 1 mM compound in 100% DMSO was titrated 1:5 by moving 10 µL 
compound into 40 µL of 100% DMSO. 6 step titration produces 1 mM ? 0.064 uM 
compound concentrations; 100% DMSO without compound is used for control points. 
Compound dilutions (including controls) were further diluted 1:5 in 1x RB, producing 
compound concentrations 200 uM ? 0.0128 uM, with DMSO at 20%. 10 µL of 
compound dilution was added to corresponding reaction. 10 µL of ATP and 10 µL of 
substrate were also added to each well. 10 µL of enzyme was added to all wells 
containing compound, as well as the positive control wells. 10 µL 1x RB added to 
negative/background control wells. After 60 minutes at room temperature, all wells 
quenched with 10 µL 0.5 M EDTA. Development of completed reaction for HTRF reader 
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involved the addition of 75 µL of Revelation Buffer consisting of the following 
components: 2 mM KF, 0.1% BSA, 0.01% Tween-20, SA-XL665, and Europium 
cryptate labeled antibody. Overnight development was allowed at 4°C. Plate was read 
using BMG Laboratories’ RUBYstar the following morning. Data analysis was done 
using Excel by Microsoft. 
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RESULTS 
 
Interpreting HTRF Data 
 As explained in the background section, the RUBYstar plate reader uses a laser to 
excite the contents in each well of a 96-well plate. The technology allows for a reading 
process that removes background fluorescence and optical clarity of the medium (Cisbio, 
2002). The reader is able to accumulate emissions at two different wavelengths; in this 
case, they are termed ‘A’ and ‘B’ counts. The B count is the emission reading at 620 nm, 
accounting for the emission from the Europium cryptate. The A count is the emission 
reading at 665 nm, representing the emission from the acceptor. This measures the FRET 
transfer, and is proportional to the amount of product that has been formed. The ratio 
used to plot data from each variation of HTRF assay is the following: 
 
(A Count / B Count)•10,000 = Ratio 
 
 Since A count is the relative number used for quantification, and it is also the 
numerator of the previous equation, it is favorable to have a large B count. By doing so it 
means that minor fluctuations in B count will not drastically affect the overall ratio. All 
wells are duplicated, and the average of the two ratios is taken prior to evaluation. 
 
Enzyme Titration 
 Assuming an adequate substrate can be obtained, and that physiological 
conditions can be replicated with the correct buffer, it is important to titrate the enzyme 
(in this case COT) (Figure 5). This will provide indications of the linear range of the 
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enzyme concentration, show the saturation point, and produce an acceptable range of 
concentrations to continue with for assay development (Figure 5). 
Figure 5: COT titration curve. The ratio was acquired by standard enzyme titration. 
 
Further timecourses are often required to show if the chosen enzyme concentration 
produces a linear range within a predetermined time period. Most often this is optimized 
as close to 60 minutes as possible, for reasons of convenience for high throughput 
screening. By titrating the enzyme it is also possible to save available resources by 
reducing needed amounts; it is essential, however, to keep the concentration high enough 
to produce an acceptable signal and signal-to-background (S/B) ratio. From Figure 5 the 
chosen COT enzyme concentration for further assay development was 25 ng/well, or a 
final experimental concentration of 13.9 nM. This is enough to produce a strong signal 
(see Figure 5), but not so much that it would saturate the experiment. 
 
 
 
 22
Timecourse 
 To further evaluate the linearity of the chosen enzyme concentration, it is 
important to produce a timecourse. This enables the visualization of not just the one 
enzyme concentration chosen (25 ng/well), but the linearity of that concentration over 
time. The chosen concentration was performed in duplicate in a horizontal fashion across 
Figure 6: COT timecourse using HTRF format. Experimental data was produced at 25 ng/well, allowing 
for optimization of the assay. 
 
a 96-well plate (Figure 6). Given that there are 12 wells across the plate, there are 12 
chosen time points: 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, and 80 minutes. The zero time 
point is considered the background, as there has been no enzyme catalysis. This was 
subtracted from all of the values during the analyzing of the data. The timecourse was 
extended beyond the desired 60 minutes to ensure the linear trend. The resulting data 
from the experiment produced a graph seen in Figure 6; several equations were also 
simultaneously calculated. A linear trend line was applied to the data point, in order to 
understand two things: first, the slope of the points; and second, the R2 value of the line. 
The slope of the line in y = mx + b form (the ‘m’ value) is also the rate of the reaction. 
This information is valuable in determining the ATP KM, as well as a checkpoint for 
y = 34.726x + 65.039
R2 = 0.9985
0
500
1000
1500
2000
2500
3000
0 20 40 60 80
Time (min)
R
at
io
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consistency between experiments. The R2 value is a useful tool to quantify exactly how 
‘linear’ the points really are. If the best fitting straight line is able to intersect with every 
point on the graph, the value will be R2 = 1. The greater the overall deviation of the 
graphed data points from a straight line, the lower the respective R2 value. Figure 6 
indicated an R2 value of 0.9881. In all timecourses, an acceptable R2 value is usually over 
0.9, though in most cases it is better to make sure that linearity is as stringent as 0.97 or 
higher. 
  
ATP KM Determination 
 Once the assay was optimized for enzyme concentration and linearity throughout 
a specific time period, the ATP KM was determined to better understand the kinetic 
properties. Since ATP competitive compounds are of major interest in our studies, it is 
important to understand the kinase’s ATP affinity. As outlined in the methods section of 
this paper, the ATP KM is determined through data collected from timecourses done at a 
wide range of ATP concentrations. For kinase COT, ATP concentrations ranged from 25 
uM to 4 mM, with time points adjusted to over three hours to make sure linearity for the 
lower concentrations was accurately measured. The slope of each linear section from 
each of the ATP concentrations constitutes a single point on Figure 7. The slope, or 
velocity of the reaction, was graphed vs. the concentration of ATP at which it was 
determined. A curve fitted to these data points was used to calculate  
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Figure 7: ATP KM for COT30-397, indicating the Vmax and KM values from the calculated trend line based 
on the experimental data. 
 
the maximum velocity (rate) and the KM. The KM was determined using the Michaelis-
Menton equation. Calculations resulted in an ATP KM of 394 uM, meaning that optimum 
conditions for identifying weakly ATP competitive compounds will be under 400 uM. 
 
IC50 Determination 
 At this point, the kinase (COT) has been characterized to the point where 
compound inhibition can be accurately tested using the HTRF assay. The experiment 
used to do this is called an IC50 determination. By definition, the IC50 is the concentration 
of a specific compound required to inhibit the enzyme activity by 50%. Since compound 
potency can vary with experimental conditions, the use of the developed conditions must 
remain constant in order to understand the relative potency of different compounds. As a 
positive control that has a low IC50 (50% inhibition is achieved at a low compound 
concentration) is used. Under the developed conditions, the chosen compounds are 
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titrated and added to the reaction. In Figure 8, Compounds 1, 2, 3, and the Control 
Compound (names withheld for proprietary purposes) were all serially diluted 1:5 in a 6-
step process, and then diluted again 1:5. These final concentrations are shown on the X-
axis of Figure 8, recorded in logarithmic order from 50 uM to 0.0032 uM.  
Figure 8: COT IC50 comparison for Compound 1, 2, and 3 versus the Control. Calculated IC50 for Cmpd. 1 
= 18.39 uM, Cmpd. 2 = >50, Cmpd. 3 = 0.0683 uM, Control = 0.481 uM. 
 
 The Y-axis indicates the percent activity at the corresponding compound 
concentration (Figure 8). This is determined in relation to both the positive and negative 
controls built into each experiment. Since the same control compound is used for every 
experiment, an IC50 of around 0.481 uM should be seen each time the experiment is 
performed. The IC50 values experimentally determined against COT in Figure 8 are as 
follows: 
  Compound 1 Compound 2 Compound 3 Control 
IC50 (uM) 18.39 >50 0.0683 0.481 
Table 1: COT IC50 values determined experimentally under developed conditions for COT. 
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Compound 2 was calculated to have an IC50 of greater than 50 uM (>50) because this is 
the highest detection limit of the assay. The curve fitting of the data analysis program can 
predict an IC50 value of greater than 50, though this value cannot be reached 
experimentally, and is of little value anyway. The lower detection limit of the assay is 
0.0032 uM, and compounds with a determined IC50 of less than 0.0032 uM are 
considered extremely potent, and most often will warrant further investigation. None of 
the compounds tested here achieved such a high level of inhibition. 
 
ATP Competition 
 In order to determine if compounds inhibit the kinases by binding to its ATP site, 
an ATP competition experiment needs to be performed. To do so, a series of IC50 values 
are determined at varying ATP concentrations. A data analysis program can produce the 
compound ki and the assumption of whether or not the compound is ATP competitive. If 
a compound is not ATP competitive, the values taken at varying ATP concentrations 
(experimental) will not match the theoretical predictions. 
Figure 9: COT ATP competition data analysis. Pink line shows theoretical values for IC50 at 100 uM, 1 
mM, and 3 mM ATP, blue line shows experimental data at the same ATP concentrations. The left graph 
indicates a compound that is ATP competitive, while the compound in the right graph is not. 
 
Computer graphing creates a graph of the theoretical points and simultaneously graphs 
the experimental points. The program is then able to indicate whether or not the 
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compound is ATP competitive based on a comparison of slopes. If the experimental slope 
is over 50% of the theoretical slope, it is defined as ATP competitive, while under 30% 
can be considered non-ATP competitive. The left graph in Figure 9 has a competitive 
percentage of 83%, indicating that compound is ATP competitive for COT, while the 
right graph has only 19%, indicating that compound is not ATP competitive for COT. 
This experiment defines not only how potent a compound is against a target kinase, but 
also the mechanism of inhibition by which it is competing with ATP. 
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DISCUSSION 
 
 As stated in the purpose, Abbott Bioresearch Center strives to create compounds 
that are able to inhibit specific kinases. Figure 1 in the background section is only a small 
portion of a much larger kinase signaling pathway, parts of which are still not understood 
and may be completely unknown. HTRF technology and inhibitor compounds have been 
adapted to explore relationships between these pathways and the compounds that are 
introduced. But even with this technology, development of the assay is still necessary for 
each individual kinase. Precise as this technology may seem to be, and as advanced as it 
really is, it is still researching processes that are millions of years old. 
 Years and sometimes decades of work by hundreds of people will be spent 
pursuing a target kinase. When a target kinase is presented to the Molecular 
Pharmacology Group, the first thing done is to gather every piece of research previously 
completed. In some cases there is very little information available, and initial reaction 
conditions and substrate identification can become tedious. Assay development is a key 
point in drug discovery, and any mistakes made will only be amplified as the project 
progresses. Incorrect development of assays can produce not only false positives, but 
false negatives. If a compound is found to be potent when in actuality it is not, it may be 
months before such evidence comes back to prove it so. Conversely, an assay may not 
show how potent a compound really is, and the next great cure might be simply overseen. 
 For these reasons, each enzyme titration is taken seriously. A difference of one 
nanogram per well in a 96-well plate may not seem like a large difference, but in small 
scale biochemistry it can drastically effect the robustness of an assay. Too little of an 
enzyme will produce lackluster signal ratios, and too much will saturate the experiment. 
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Not to mention that the number of compounds screened numbers in the thousands, and 
saving micrograms per plate can result in thousands of savings per year. 
 Timecourses allow for the manipulation of linearity during development. While 
titrations produce data relative to the amounts needed to optimize the assay, a timecourse 
can show the variations in rate for those chosen concentrations. Some enzymes exhibit 
lag phases and other individual traits, each of which can help identify problems that may 
occur at a later time. While it may have become standard to have reaction times of 60 
minutes, it is not out of the ordinary to stop reactions sooner or allow them to proceed for 
a longer period of time. It is not so much the actual components of the final assay and 
their concentrations, but whether the true characteristics of the enzyme are shown in 
response to compound inhibition experiments. Development of an assay is truly put to the 
test, as mentioned in the results section, when an ATP competition experiment is 
performed. 
 At this point a compound has been identified as being an inhibitor of COT 
enzyme function, and it was determined to inhibit in an ATP competitive manner. From 
this point onwards, the compound is handled by in vivo labs that will begin to test the 
compound’s toxicity levels. 
 In the increasingly competitive field of drug discovery and pharmaceuticals, 
Abbott Bioresearch Center has adapted to the use of HTRF technology in order to 
increase the number of compounds that can be screened daily. The development of assays 
is done in singular, bench experiments. It becomes another development and 
troubleshooting process entirely when upscaling HTRF assays for medium and high 
throughput use. In many ways robots are more efficient than humans, but in every other 
way they are only as advanced as we can make them. High throughput science is another 
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area entirely, and the assay development is become more focused on meeting the needs of 
such technologically advanced environments. Fortunately, many companies have been 
successful in discovering new drugs, and for this it is worth the great amounts of time and 
resources that are required. 
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